IVIG To SCIG Transition denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to the IVIG-to-SCIG Transition

Blue Cross Blue Shield quantity-limit (QL) denials for the IVIG-to-SCIG transition typically arise when the authorized supply of SCIG — number of vials, grams, or infusion kits per dispensing period — does not match the prescriber's ordered quantity. SCIG dosing is individualized: the prescriber calculates the patient's dose based on the patient's body weight and current IVIG dose, following the specific SCIG product's FDA-approved conversion methodology. If the prescribed quantity exceeds the plan's standard limit, a quantity-limit exception is the appropriate pathway.

## Why This Denial Is Appealable

Quantity limits must have a clinical basis, and when the prescribed quantity reflects individualized dosing per the FDA label and specialist calculation, there is a strong case that the limit is not clinically appropriate for this patient. Under ACA §2719, QL denials are adverse benefit determinations subject to internal appeal and then external review by an independent organization. Under ERISA §503, employer-plan members are entitled to full-and-fair review. File internally within the deadline on your EOB (often 180 days) and, if denied, request external review within the typical 4-month window. Expedited review is available for urgent clinical situations.

## The Concrete Appeal Process

1. Obtain the BCBS quantity-limit policy for the specific SCIG product — confirm the exact limit being applied. 2. Have the prescriber document the individualized dose calculation, sourced from the FDA-approved prescribing label's dosing and administration section. 3. Submit an internal appeal with the prescriber's calculation, chart weight documentation, and a cover letter explaining why the prescribed quantity is medically necessary. 4. If denied, escalate to external review with the same package.

## Documentation to Gather

• Individualized dose calculation: The prescriber's written calculation showing how the ordered quantity was derived, referencing the FDA label's dosing methodology (not specific numbers in this appeal guidance — your prescriber will supply the actual figures from the label).
• Current body weight from chart: The specific chart entry the prescriber used as the basis for dosing.
• Current IVIG dose history: Records of the IVIG dose the patient has been receiving, which typically forms the starting point for the SCIG conversion.
• FDA prescribing label: For the ordered SCIG product, showing the approved dosing and conversion approach.
• Prescriber medical-necessity letter: Affirms that the prescribed quantity is the individualized, label-based dose for this patient and that a reduced quantity would provide subtherapeutic immunoglobulin replacement.
• Diagnosis and clinical status: Chart notes confirming ongoing need for immunoglobulin replacement.

## Criteria-Mapping Structure

Obtain both the BCBS quantity-limit policy and the FDA label's dosing section. Map each relevant criterion:

| Quantity Limit Criterion / Label Dosing Step | Patient-Specific Evidence | |---|---| | [BCBS standard limit as stated in policy] | [Prescriber's individualized calculation referencing label] | | [Label conversion methodology step] | [Chart weight, prior IVIG dose, calculated SCIG quantity] |

The key argument: the limit is not medically appropriate when applied to an individualized, label-derived dose for this patient's specific weight and clinical profile.